ZA97521B - 19-Nor-pregnene derivatives. - Google Patents

19-Nor-pregnene derivatives.

Info

Publication number
ZA97521B
ZA97521B ZA9700521A ZA97521A ZA97521B ZA 97521 B ZA97521 B ZA 97521B ZA 9700521 A ZA9700521 A ZA 9700521A ZA 97521 A ZA97521 A ZA 97521A ZA 97521 B ZA97521 B ZA 97521B
Authority
ZA
South Africa
Prior art keywords
pregnene derivatives
pregnene
derivatives
Prior art date
Application number
ZA9700521A
Other languages
English (en)
Inventor
Alain Piasco
Jean Lafay
Remi Delansome
Jacques Paris
Jean-Claude Pascal
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of ZA97521B publication Critical patent/ZA97521B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/006Ketals at position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9700521A 1996-01-22 1997-01-22 19-Nor-pregnene derivatives. ZA97521B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives

Publications (1)

Publication Number Publication Date
ZA97521B true ZA97521B (en) 1997-08-04

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9700521A ZA97521B (en) 1996-01-22 1997-01-22 19-Nor-pregnene derivatives.

Country Status (36)

Country Link
US (1) US6180803B1 (ko)
EP (2) EP0785212A1 (ko)
JP (2) JP4368945B2 (ko)
KR (1) KR100396902B1 (ko)
CN (1) CN1187366C (ko)
AP (1) AP1176A (ko)
AR (1) AR005500A1 (ko)
AT (1) ATE184015T1 (ko)
BR (1) BR9707064A (ko)
CA (1) CA2243504C (ko)
CO (1) CO4810230A1 (ko)
CZ (1) CZ292047B6 (ko)
DE (1) DE69700470T2 (ko)
DZ (1) DZ2169A1 (ko)
EE (1) EE03692B1 (ko)
ES (1) ES2140961T3 (ko)
GR (1) GR3031954T3 (ko)
HK (1) HK1018216A1 (ko)
HU (1) HU221796B1 (ko)
ID (1) ID15840A (ko)
IL (1) IL125379A (ko)
IS (1) IS1902B (ko)
JO (1) JO1971B1 (ko)
MY (1) MY116845A (ko)
NO (1) NO309572B1 (ko)
NZ (1) NZ330954A (ko)
OA (1) OA10813A (ko)
PE (1) PE55998A1 (ko)
PL (1) PL185608B1 (ko)
RU (1) RU2166509C2 (ko)
SI (1) SI0886645T1 (ko)
TN (1) TNSN97015A1 (ko)
TR (1) TR199801399T2 (ko)
TW (1) TW411345B (ko)
WO (1) WO1997027210A1 (ko)
ZA (1) ZA97521B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
KR100856523B1 (ko) 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
WO2005020880A2 (en) * 2003-09-03 2005-03-10 Miscon Trading S.A. Methods for the treatment of endometriosis
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー.ブイ. 皮膚残渣を最小限に抑えるための経皮的医薬製剤
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109481450B (zh) * 2015-09-02 2021-07-23 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
AP1176A (en) 2003-06-30
PL327998A1 (en) 1999-01-04
TR199801399T2 (xx) 1998-10-21
EP0886645A1 (en) 1998-12-30
IS4800A (is) 1998-07-21
GR3031954T3 (en) 2000-03-31
TW411345B (en) 2000-11-11
KR100396902B1 (ko) 2004-05-03
JP4368945B2 (ja) 2009-11-18
IL125379A0 (en) 1999-03-12
ES2140961T3 (es) 2000-03-01
RU2166509C2 (ru) 2001-05-10
PE55998A1 (es) 1998-10-01
CA2243504C (en) 2004-03-30
JP2000503980A (ja) 2000-04-04
CZ230798A3 (cs) 1998-11-11
AP9801299A0 (en) 1998-09-30
CZ292047B6 (cs) 2003-07-16
AU1595597A (en) 1997-08-20
AU708135B2 (en) 1999-07-29
HUP9900684A2 (hu) 1999-07-28
JP2009167188A (ja) 2009-07-30
CN1209811A (zh) 1999-03-03
EE9800219A (xx) 1998-12-15
NO983356L (no) 1998-07-21
AR005500A1 (es) 1999-06-23
WO1997027210A1 (en) 1997-07-31
CA2243504A1 (en) 1997-07-31
CO4810230A1 (es) 1999-06-30
IL125379A (en) 2003-05-29
NO983356D0 (no) 1998-07-21
DE69700470D1 (de) 1999-10-07
JO1971B1 (en) 1997-12-15
HUP9900684A3 (en) 1999-11-29
OA10813A (en) 2003-01-28
NZ330954A (en) 1998-10-28
KR19990081895A (ko) 1999-11-15
HU221796B1 (hu) 2003-01-28
CN1187366C (zh) 2005-02-02
SI0886645T1 (en) 1999-12-31
PL185608B1 (pl) 2003-06-30
TNSN97015A1 (fr) 2005-03-15
HK1018216A1 (en) 1999-12-17
MY116845A (en) 2004-04-30
ID15840A (id) 1997-08-14
US6180803B1 (en) 2001-01-30
EP0886645B1 (en) 1999-09-01
ATE184015T1 (de) 1999-09-15
DE69700470T2 (de) 2000-03-30
EE03692B1 (et) 2002-04-15
DZ2169A1 (fr) 2002-12-25
NO309572B1 (no) 2001-02-19
BR9707064A (pt) 1999-12-28
IS1902B (is) 2003-11-20
EP0785212A1 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
ZA97521B (en) 19-Nor-pregnene derivatives.
ZA9710429B (en) Broad-spectrumδ-endotoxins.
ZA979199B (en) Aminothiophenecarboxamides.
ZA976168B (en) 3-Ureido-pyridofurans and -pyridothiophenes.
ZA961444B (en) Pyrazolylbenzoyl derivatives.
ZA979593B (en) Naphthyridine derivatives.
ZA977206B (en) Arylalkanoylpyridazines.
ZA978304B (en) 3-alkyl-3-phenyl-piperidines.
ZA961449B (en) Isoxazolylbenzoyl derivatives.
HK1018457A1 (en) Alkylaminobenzothiazole and-benzoxazole derivatives.
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA979725B (en) Benzoaxozole derivative.
ZA982436B (en) Thiazolimine derivatives.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA97572B (en) 1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA974052B (en) New benzothiazolinones.
ZA976022B (en) Cycloalkano-pyridines.
CY2322B1 (en) Benzoaeguequinoline derivatives.
ZA971167B (en) Heterocyclyl-ergoline derivatives.
ZA971466B (en) Endothelin-receptor-antagonists.
ZA988206B (en) Piperidinylmethyloxazolidinone derivative.